Superworth

Liminatus Pharma EPS LIMN

Diluted earnings per share by quarter and over the last twelve months, from 2024.

Last 12 months, to Jun 30, 2026
−$21.50
Latest quarter, Q2 FY26
−$1.50
Fiscal year 2025
−$19.50

Liminatus Pharma's earnings per share was −$21.50 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.50.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$19.50n/a
FY2024−$128.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.50n/a−$21.50
Q1 FY26−$1.50n/a−$20.00
Q4 FY25−$15.00n/a−$19.50
Q3 FY25−$3.50n/a−$5.00
Q2 FY25$0.00n/a−$3.00
Q1 FY25−$1.00n/a−$5.50
Q4 FY24−$0.50n/a−$128.00
Q3 FY24−$1.50n/an/a
Q2 FY24−$2.50n/an/a
Q1 FY24−$123.50n/an/a

Against its peers

Companies in Healthcare nearest Liminatus Pharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
LIMNLiminatus Pharma−$21.50
OXBROXBRIDGE RE HOLDINGS$0.02
EDUCEducational Development$0.19
GTIMGood Times Restaurants$0.21+75% a year
MDRRMedalist Diversified$3.84
BCGBinah Capital$0.16
VIPVulcan Infrastructure & Power$0.07
MXCMexco Energy$0.75−5% a year
CKXCKX Lands$1.42+647% a year
MSGMMotorsport Games$0.43+187% a year
ATCHAtlasClear$0.01
Peer median$0.20

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Liminatus Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.